Histiocytosis Clinical Trial
Official title:
Molecular Targets for the Treatment of Histiocytosis
The primary objective: to develop technical and operating procedures for detection mutations of histiocytosis during clinical practice of no-specialized molecular platforms, for diagnosis and follow-up of the disease. The secondary objectives: to describe therapeutic target mutations in histiocytosis patients, and to develop the cellular tests to evaluate in vitro the sensibility of these mutations drive to inhibitors.
The study is ancillary of the French "Gene Histio" cohort (patients already included) and "HISTIO target 2020" cohort (patients recruited since may 2020). The data base of the French registry of histiocytoses is held by Dr J. Donadieu, and localized in Trousseau hospital (APHP) 75012 Paris, France, where server and backup are kept. 5 teams contributes to the study with different role: Team 1 is responsible for histology diagnosis, selection of histiocyte- rich areas, extraction of nucleic acids and detection of the BRAF p.V600E mutations. This group is also responsible of the tissue and nucleic acids biobank. Team 2 is responsible for the collection of clinical data and tissue and blood samples of the children. This group is also responsible of the clinical data base. Team 3 is responsible for the collection of clinical data and tissue and blood samples of the adult patients. Team 4 is responsible for the development and validation of the new methods of detection of genetic somatic alterations described in project, and will perform most of the molecular analyses and interpretations. Team 5 is responsible for regulatory requirements preparation and submissions and takes care of replying to regulatory comments and amendments until getting approvals. The project manager will also take care of the coordination of all activities related to the database setting and utilization, liaising between researchers, doctors and operational team. Team 5 will be in charge of the data management of the database and will ensure collection tools, integration and availability of data at appropriate quality. The data manager ensures that data is collected, validated, complete, and consistent, to provide a high quality and comprehensive database to the statistics team. Team 5 includes also a statistician who will perform data analysis according to a detailed statistical analysis plan to be developed once the project is approved. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01049854 -
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
|
Phase 2 | |
| Recruiting |
NCT05915208 -
Histiocytic Disorder Follow-up Study
|
||
| Terminated |
NCT01050439 -
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT00145626 -
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
|
Phase 2 | |
| Not yet recruiting |
NCT05803629 -
Characterizing Histiocytosis With 68Ga-FAPI PET/CT
|
N/A | |
| Recruiting |
NCT04665674 -
Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
|
||
| Terminated |
NCT02012231 -
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
|
Phase 1 | |
| Completed |
NCT01225718 -
Ceftriaxone in Non-neutropenic Fever
|
N/A | |
| Active, not recruiting |
NCT03127709 -
A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis
|
||
| Recruiting |
NCT05786924 -
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
|
Phase 1 | |
| Recruiting |
NCT04943224 -
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
|
Phase 2 | |
| Recruiting |
NCT04943198 -
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
|
Phase 2 | |
| Recruiting |
NCT04943211 -
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
|
Phase 3 |